Efficacy and safety of IL-23p19 and IL-12/23p40 inhibitors in moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.

ABSTRACT:

Background

Interleukin (IL)-23 inhibitors-including IL-23p19 inhibitors (guselkumab, mirikizumab, risankizumab) and the IL-12/23p40 inhibitor ustekinumab-are emerging treatments for Crohn's disease (CD), but comparative data among them remain limited. Most previous network meta-analyses (NMAs) compared IL-23 inhibitors with other biologic classes or examined a specific IL-23 inhibitor against multiple comparators, often excluding some trials due to design heterogeneity or publication timing. Safety outcomes were also underreported. We conducted the first comprehensive NMA focused exclusively on IL-23 inhibitors to provide practice-oriented evidence.

Methods

We systematically searched PubMed, Embase, and Cochrane CENTRAL on May 11, 2025, for randomised controlled trials (RCTs

SUBMITTER: Kaneko M 

PROVIDER: S-EPMC12677037 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature